PT - JOURNAL ARTICLE AU - Wagner, Ralf AU - Peterhoff, David AU - Beileke, Stephanie AU - Guenther, Felix AU - Berr, Melanie AU - Einhauser, Sebastian AU - Schütz, Anja AU - Niller, Hans Helmut AU - Steininger, Philipp AU - Knöll, Antje AU - Tenbusch, Matthias AU - Maier, Clara AU - Korn, Klaus AU - Stark, Klaus J. AU - Gessner, Andre AU - Burkhardt, Ralph AU - Kabesch, Michael AU - Schedl, Holger AU - Küchenhoff, Helmut AU - Pfahlberg, Annette B. AU - Heid, Iris M. AU - Gefeller, Olaf AU - Überla, Klaus TI - Estimates and determinants of SARS-CoV-2 seroprevalence and infection fatality ratio using latent class analysis: the population-based Tirschenreuth study in the hardest-hit German county in spring 2020 AID - 10.1101/2021.03.29.21254343 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.29.21254343 4099 - http://medrxiv.org/content/early/2021/04/04/2021.03.29.21254343.short 4100 - http://medrxiv.org/content/early/2021/04/04/2021.03.29.21254343.full AB - SARS-CoV-2 infection fatality ratios (IFR) remain controversially discussed with implications for political measures, but the number of registered infections depends on testing strategies and deduced case fatality ratios (CFR) are poor proxies for IFR. The German county of Tirschenreuth suffered a severe SARS-CoV-2 outbreak in spring 2020 with particularly high CFR.To estimate seroprevalence, dark figure, and IFR for the Tirschenreuth population aged ≥14 years in June/July 2020 with misclassification error control, we conducted a population-based study, including home visits for elderly, and analyzed 4203 participants for SARS-CoV-2 antibodies via three antibody tests (64% of our random sample). Latent class analysis yielded 8.6% standardized county-wide seroprevalence, dark figure factor 5.0, and 2.5% overall IFR. Seroprevalence was two-fold higher among medical workers and one third among current smokers with similar proportions of registered infections. While seroprevalence did not show an age-trend, the dark figure was 12.2 in the young versus 1.7 for ≥85-year-old. Age-specific IFRs were <0.5% below 60 years of age, 1.0% for age 60-69, 13.2% for age 70+, confirming a previously reported age-model for IFR. Senior care homes accounted for 45% of COVID-19-related deaths, reflected by an IFR of 7.5% among individuals aged 70+ and an overall IFR of 1.4% when excluding senior care home residents from our computation.Our data underscore senior care home infections as key determinant of IFR additionally to age, insufficient targeted testing in the young, and the need for further investigations on behavioral or molecular causes of the fewer infections among current smokers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bavarian States Ministry of Science and Arts (StMWK; grant to R.W and K.U.) as well as by the National Research Network of the University Medicine (NUM; applied surveillance and testing; B-FAST) to K.U. and R.W.. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The TiKoCo study was approved by the Ethics Committee of the University of Regensburg, Germany (vote 12-101-0258) and adopted by the Ethics Committee of the University of Erlangen (vote 248_20 Bc).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll authors declare that data and materials and codes will be made available.